CN111110677A - 用于治疗精神分裂症的组合物 - Google Patents

用于治疗精神分裂症的组合物 Download PDF

Info

Publication number
CN111110677A
CN111110677A CN202010012498.9A CN202010012498A CN111110677A CN 111110677 A CN111110677 A CN 111110677A CN 202010012498 A CN202010012498 A CN 202010012498A CN 111110677 A CN111110677 A CN 111110677A
Authority
CN
China
Prior art keywords
compound
formulation
pharmaceutical formulation
sleep
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010012498.9A
Other languages
English (en)
Chinese (zh)
Inventor
R.鲁斯林格
奥山昌弘
N.罗尔
S.瓦纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CN111110677A publication Critical patent/CN111110677A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202010012498.9A 2014-12-02 2015-11-30 用于治疗精神分裂症的组合物 Pending CN111110677A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462086691P 2014-12-02 2014-12-02
US62/086691 2014-12-02
US201562248071P 2015-10-29 2015-10-29
US62/248071 2015-10-29
CN201580065471.3A CN107567444A (zh) 2014-12-02 2015-11-30 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580065471.3A Division CN107567444A (zh) 2014-12-02 2015-11-30 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物

Publications (1)

Publication Number Publication Date
CN111110677A true CN111110677A (zh) 2020-05-08

Family

ID=54848909

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010012498.9A Pending CN111110677A (zh) 2014-12-02 2015-11-30 用于治疗精神分裂症的组合物
CN201580065471.3A Pending CN107567444A (zh) 2014-12-02 2015-11-30 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580065471.3A Pending CN107567444A (zh) 2014-12-02 2015-11-30 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物

Country Status (26)

Country Link
US (7) US9458130B2 (enExample)
EP (2) EP4063357A1 (enExample)
JP (4) JP2018501217A (enExample)
KR (1) KR102620681B1 (enExample)
CN (2) CN111110677A (enExample)
AU (4) AU2015355226B2 (enExample)
BR (1) BR112017011555B1 (enExample)
CA (1) CA2968977A1 (enExample)
CL (2) CL2017001376A1 (enExample)
CO (1) CO2017005498A2 (enExample)
DK (1) DK3227273T3 (enExample)
EA (1) EA201791226A1 (enExample)
ES (1) ES2910528T3 (enExample)
HU (1) HUE058212T2 (enExample)
IL (4) IL313572A (enExample)
MX (1) MX385586B (enExample)
MY (1) MY185516A (enExample)
PE (1) PE20171646A1 (enExample)
PH (1) PH12017501007B1 (enExample)
PL (1) PL3227273T3 (enExample)
PT (1) PT3227273T (enExample)
SG (1) SG11201704332YA (enExample)
TW (1) TWI694069B (enExample)
UA (1) UA122780C2 (enExample)
WO (1) WO2016089766A1 (enExample)
ZA (1) ZA201703481B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2968977A1 (en) 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
SG11201810358YA (en) 2016-05-25 2018-12-28 Mitsubishi Tanabe Pharma Corp Compositions and methods for treating negative symptoms in non-schizophrenic patients
EP3641732A1 (en) * 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
CN107721988A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 具有抗炎活性的异吲哚‑1‑酮类化合物
WO2020041504A1 (en) * 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
TWI841545B (zh) * 2018-12-12 2024-05-11 日商田邊三菱製藥股份有限公司 耐胃性控制釋放經口劑型
US12441701B2 (en) * 2019-06-28 2025-10-14 Tapi Czech Industries S.R.O. Solid state forms of roluperidone and salts thereof
US20230190870A1 (en) 2020-05-20 2023-06-22 The Board Of Trustees Of The University Of Illinois Method for Treating Lysosomal Storage Diseases with Histatin Peptides
CN116251078B (zh) * 2021-12-09 2025-12-19 河北以岭医药研究院有限公司 一种盐酸度洛西汀肠溶胶囊及其制备方法
CA3243767A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. USE OF ROLUPERIDONE IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1426405A (zh) * 2000-02-29 2003-06-25 三菱制药株式会社 新型环状酰胺衍生物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
ZA908641B (en) 1989-10-27 1992-06-24 Du Pont (n-phthalimidoalkyl)piperidines
FR2797643B1 (fr) 1999-08-17 2003-06-06 Rhodia Chimie Sa Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures
BR0208306A (pt) 2001-03-26 2004-03-09 Novartis Ag Composições farmacêuticas
DOP2006000125A (es) 2005-06-06 2006-12-31 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
EP4070794A3 (en) * 2010-07-20 2023-01-18 Minerva Neurosciences, Inc. Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders
EP3335731B1 (en) * 2010-07-20 2024-09-04 Minerva Neurosciences, Inc. Use of cyclic amide derivatives to treat sleep disorders
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP2685966A1 (en) * 2011-03-17 2014-01-22 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
WO2015191554A1 (en) * 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
CA2968977A1 (en) * 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
SG11201810358YA (en) 2016-05-25 2018-12-28 Mitsubishi Tanabe Pharma Corp Compositions and methods for treating negative symptoms in non-schizophrenic patients
EP3641732A1 (en) 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
WO2020041504A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1426405A (zh) * 2000-02-29 2003-06-25 三菱制药株式会社 新型环状酰胺衍生物

Also Published As

Publication number Publication date
SG11201704332YA (en) 2017-06-29
US20160152597A1 (en) 2016-06-02
US20210228561A1 (en) 2021-07-29
US10799493B2 (en) 2020-10-13
CL2017001376A1 (es) 2018-02-16
US20170042877A1 (en) 2017-02-16
EP3227273A1 (en) 2017-10-11
US9730920B2 (en) 2017-08-15
AU2021229240A1 (en) 2021-10-07
CN107567444A (zh) 2018-01-09
EP4063357A1 (en) 2022-09-28
MY185516A (en) 2021-05-19
ZA201703481B (en) 2023-12-20
PL3227273T3 (pl) 2022-05-30
JP2022105159A (ja) 2022-07-12
IL301320A (en) 2023-05-01
IL252347A0 (en) 2017-07-31
MX2017007065A (es) 2017-12-18
NZ732033A (en) 2023-10-27
JP2018501217A (ja) 2018-01-18
EP3227273B1 (en) 2022-02-09
NZ770365A (en) 2023-10-27
HUE058212T2 (hu) 2022-07-28
CO2017005498A2 (es) 2017-09-20
MX385586B (es) 2025-03-18
KR102620681B1 (ko) 2024-01-04
US20250195494A1 (en) 2025-06-19
IL301320B2 (en) 2024-11-01
EA201791226A1 (ru) 2017-09-29
PE20171646A1 (es) 2017-11-13
AU2020204286B2 (en) 2021-06-17
JP2025004090A (ja) 2025-01-14
IL280052A (en) 2021-03-01
AU2021229240B2 (en) 2023-08-24
BR112017011555B1 (pt) 2023-10-03
IL313572A (en) 2024-08-01
IL301320B1 (en) 2024-07-01
US10258614B2 (en) 2019-04-16
KR20170106310A (ko) 2017-09-20
JP7069253B2 (ja) 2022-05-17
AU2015355226A1 (en) 2017-06-08
JP2020172531A (ja) 2020-10-22
AU2023258386A1 (en) 2023-11-23
DK3227273T3 (da) 2022-05-02
CA2968977A1 (en) 2016-06-09
US20200022968A1 (en) 2020-01-23
PH12017501007A1 (en) 2017-12-18
CL2021000044A1 (es) 2021-06-04
TWI694069B (zh) 2020-05-21
AU2020204286A1 (en) 2020-07-16
PT3227273T (pt) 2022-04-06
IL280052B1 (en) 2023-05-01
IL252347B (en) 2021-01-31
UA122780C2 (uk) 2021-01-06
AU2023258386B2 (en) 2025-10-23
US9458130B2 (en) 2016-10-04
BR112017011555A2 (pt) 2018-01-09
US20180153871A1 (en) 2018-06-07
TW201632511A (zh) 2016-09-16
US20230201184A1 (en) 2023-06-29
ES2910528T3 (es) 2022-05-12
WO2016089766A1 (en) 2016-06-09
AU2015355226B2 (en) 2020-04-02
IL280052B2 (en) 2023-09-01
PH12017501007B1 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
AU2023258386B2 (en) Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN115154470B (zh) 使用食欲素-2受体拮抗剂治疗抑郁症的方法
BR122023014589B1 (pt) Usos de formulação farmacêutica que compreende di-hidrato de monocloridrato de 2-((1-(2-(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil) isoindolin-1-ona
NZ770365B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
EA040638B1 (ru) Фармацевтический состав, содержащий 2-((1-(2-(4-фторфенил)-2-оксоэтил)пиперидин-4-ил)метил)изоиндолин-1-он для лечения психоневрологического заболевания или расстройства сна, способ лечения психоневрологического заболевания или расстройства сна, таблетка и набор
NZ732033B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination